SM
RXIIW

Sabby Management’s RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 RXIIW Stock Holding History

Sabby Management’s Portfolio RXIIW Stock Details RXIIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-195,259
Closed -$68K – 156
2018
Q3 		$68K Sell
195,259
-963
-0.5% -$458 0.01% 107
2018
Q2 		$49K Sell
196,222
-300
-0.2% -$130 0.01% 120
2018
Q1 		$88K Sell
196,522
-1,904,275
-91% -$1.24M 0.01% 135
2017
Q4 		$273K Hold
2,100,797
– – 0.02% 116
2017
Q3 		$355K Sell
2,100,797
-119,695
-5% -$23K 0.02% 113
2017
Q2 		$400K Sell
2,220,492
-17,995
-0.8% -$3.53K 0.03% 154
2017
Q1 		$492K Sell
2,238,487
-31,796
-1% -$5.62K 0.03% 180
2016
Q4 		$454K Buy
+2,270,283
New +$409K 0.03% 202

Sabby Management's RXIIW Position: Q4 2018 in Review

Sabby Management sold out of RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) in Q4 2018, closing a stake of 195,259 shares — an estimated $68K sold.

Sabby Management first reported a position in RXIIW in Q4 2016 and held it in 8 quarters. The position peaked at $492K in Q1 2017. 0 funds tracked by Wall St. Rank hold RXIIW as of Q4 2018.

  • Sabby Management reported no remaining RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 195,259 RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 shares in Q4 2018, an estimated $68K.
  • Sabby Management first reported a position in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 in Q4 2016 and held it in 8 quarters.
  • Sabby Management's RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 position peaked at $492K in Q1 2017.
  • 0 funds tracked by Wall St. Rank held RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.